Literature DB >> 24647028

Association of type 2 diabetes with brain atrophy and cognitive impairment.

Rosebud O Roberts1, David S Knopman, Scott A Przybelski, Michelle M Mielke, Kejal Kantarci, Gregory M Preboske, Matthew L Senjem, Vernon S Pankratz, Yonas E Geda, Bradley F Boeve, Robert J Ivnik, Walter A Rocca, Ronald C Petersen, Clifford R Jack.   

Abstract

OBJECTIVE: We investigated the associations of diabetes and hypertension with imaging biomarkers (markers of neuronal injury and ischemic damage) and with cognition in a population-based cohort without dementia.
METHODS: Participants (n = 1,437, median age 80 years) were evaluated by a nurse and physician and underwent neuropsychological testing. A diagnosis of cognitively normal, mild cognitive impairment (MCI), or dementia was made by an expert panel. Participants underwent MRI to determine cortical and subcortical infarctions, white matter hyperintensity (WMH) volume, hippocampal volume (HV), and whole brain volume (WBV). The medical records were reviewed for diabetes and hypertension in midlife or later.
RESULTS: Midlife diabetes was associated with subcortical infarctions (odds ratio, 1.85 [95% confidence interval, 1.09-3.15]; p = 0.02), reduced HV (-4% [-7 to -1.0]; p = 0.01), reduced WBV (-2.9% [-4.1 to -1.6]), and prevalent MCI (odds ratio, 2.08; p = 0.01). The association between diabetes and MCI persisted with adjustment for infarctions and WMH volume but was attenuated after adjustment for WBV (1.60 [0.87-2.95]; p = 0.13) and HV (1.82 [1.00-3.32]; p = 0.05). Midlife hypertension was associated with infarctions and WMH volume and was marginally associated with reduced performance in executive function. Effects of late-life onset of diabetes and hypertension were few.
CONCLUSIONS: Midlife onset of diabetes may affect late-life cognition through loss of brain volume. Midlife hypertension may affect executive function through ischemic pathology. Late-life onset of these conditions had fewer effects on brain pathology and cognition.

Entities:  

Mesh:

Year:  2014        PMID: 24647028      PMCID: PMC3966799          DOI: 10.1212/WNL.0000000000000269

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

Review 1.  Advanced glycation end-products: a review.

Authors:  R Singh; A Barden; T Mori; L Beilin
Journal:  Diabetologia       Date:  2001-02       Impact factor: 10.122

2.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

3.  Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD).

Authors:  Dieter Edbauer; Michael Willem; Sven Lammich; Harald Steiner; Christian Haass
Journal:  J Biol Chem       Date:  2002-01-23       Impact factor: 5.157

4.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.

Authors:  Rita Peila; Beatriz L Rodriguez; Lenore J Launer
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

5.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.

Authors:  M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen
Journal:  BMJ       Date:  2001-06-16

6.  Advanced glycation end product level, diabetes, and accelerated cognitive aging.

Authors:  Kristine Yaffe; K Lindquist; A V Schwartz; C Vitartas; E Vittinghoff; S Satterfield; E M Simonsick; L Launer; C Rosano; J A Cauley; T Harris
Journal:  Neurology       Date:  2011-09-07       Impact factor: 9.910

7.  Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI.

Authors:  T den Heijer; S E Vermeer; E J van Dijk; N D Prins; P J Koudstaal; A Hofman; M M B Breteler
Journal:  Diabetologia       Date:  2003-11-01       Impact factor: 10.122

Review 8.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

9.  Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study.

Authors:  Reinhold Schmidt; Lenore J Launer; Lars-Göran Nilsson; Andrzej Pajak; Susanna Sans; Klaus Berger; Monique M Breteler; Maria de Ridder; Carole Dufouil; Rebecca Fuhrer; Simona Giampaoli; Albert Hofman
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

10.  FLAIR histogram segmentation for measurement of leukoaraiosis volume.

Authors:  C R Jack; P C O'Brien; D W Rettman; M M Shiung; Y Xu; R Muthupillai; A Manduca; R Avula; B J Erickson
Journal:  J Magn Reson Imaging       Date:  2001-12       Impact factor: 4.813

View more
  74 in total

1.  Interleukin-6, interleukin-6 receptor gene variant, small-vessel disease and incident dementia.

Authors:  K Miwa; S Okazaki; M Sakaguchi; H Mochizuki; K Kitagawa
Journal:  Eur J Neurol       Date:  2016-01-03       Impact factor: 6.089

2.  Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology.

Authors:  Katherine J Bangen; Jayandra J Himali; Alexa S Beiser; Daniel A Nation; David J Libon; Caroline S Fox; Sudha Seshadri; Philip A Wolf; Ann C McKee; Rhoda Au; Lisa Delano-Wood
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

3.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

Review 4.  Disturbed sleep and diabetes: A potential nexus of dementia risk.

Authors:  Calliope Holingue; Alexandra Wennberg; Slava Berger; Vsevolod Y Polotsky; Adam P Spira
Journal:  Metabolism       Date:  2018-02-01       Impact factor: 8.694

5.  HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition.

Authors:  Minjie Wu; Omalara Fatukasi; Shaolin Yang; Jeffery Alger; Peter B Barker; Hoby Hetherington; Tae Kim; Andrew Levine; Eileen Martin; Cynthia A Munro; Todd Parrish; Ann Ragin; Ned Sacktor; Eric Seaberg; James T Becker
Journal:  AIDS       Date:  2018-08-24       Impact factor: 4.177

6.  Multimorbidity and neuroimaging biomarkers among cognitively normal persons.

Authors:  Maria Vassilaki; Jeremiah A Aakre; Michelle M Mielke; Yonas E Geda; Walter K Kremers; Rabe E Alhurani; Mary M Machulda; David S Knopman; Ronald C Petersen; Val J Lowe; Clifford R Jack; Rosebud O Roberts
Journal:  Neurology       Date:  2016-04-13       Impact factor: 9.910

7.  High Blood Lead Levels: An Increased Risk for Development of Brain Hyperintensities among Type 2 Diabetes Mellitus Patients.

Authors:  Hafsa Suhail Najim Al-Anbari; Dawser K Ismail; Mohammed Khudair Hasan; Qutaiba Ahmed Al Khames Aga; Pottathil Shinu; Anroop B Nair
Journal:  Biol Trace Elem Res       Date:  2020-08-31       Impact factor: 3.738

8.  Circulating Vascular Growth Factors and Magnetic Resonance Imaging Markers of Small Vessel Disease and Atrophy in Middle-Aged Adults.

Authors:  Mekala R Raman; Jayandra J Himali; Sarah C Conner; Charles DeCarli; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri; Pauline Maillard; Claudia L Satizabal
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

9.  Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults.

Authors:  Vijay K Ramanan; Scott A Przybelski; Jonathan Graff-Radford; Anna M Castillo; Val J Lowe; Michelle M Mielke; Rosebud O Roberts; Robert I Reid; David S Knopman; Clifford R Jack; Ronald C Petersen; Prashanthi Vemuri
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.

Authors:  Jamaica R Rettberg; Ha Dang; Howard N Hodis; Victor W Henderson; Jan A St John; Wendy J Mack; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2016-01-29       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.